Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01733407 · ClinicalTrials.gov registry record · Phase 1
L-Serine Supplementation in Hereditary Sensory Neuropathy Type 1
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01733407: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT01733407 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01733407, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
In hereditary sensory and autonomic neuropathy type 1 (HSAN1) the investigators recently discovered the accumulation of two neurotoxic sphingolipids. It appears that these lipids arise as the mutant enzyme has a reduced affinity for its normal preferred substrate L-serine. The investigators now plan to perform a two year study of L-serine supplementation to correct the biochemistry and neurological disease in humans with HSAN1. In the course the investigators will also establish correlations between an existing neurological rating scale of sensory neuropathy and intraepidermal nerve fiber density. Funding Source - FDA OOPD
Interventions
- DRUG placebo
- DRUG L-serine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2013-09 |
| Est. Completion | 2017-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01733407
The ClinicalTrials.gov registry entry for NCT01733407 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01733407 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01733407 about?
NCT01733407 is a clinical study titled "L-Serine Supplementation in Hereditary Sensory Neuropathy Type 1". In hereditary sensory and autonomic neuropathy type 1 (HSAN1) the investigators recently discovered the accumulation of two neurotoxic sphingolipids. It appears that these lipids arise as the mutant enzyme has a reduced affinity for its normal preferred substrate L-serine. The investigators now plan...
What is the current status of trial NCT01733407?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2013-09. Estimated completion is 2017-07.
What interventions are being tested in trial NCT01733407?
The interventions under investigation include: placebo (DRUG), L-serine (DRUG).
Who is sponsoring clinical trial NCT01733407?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.